Celluris, a leader in innovative therapies for cancer treatment, has recently been recognized as a Deep Tech Pioneer by Hello Tomorrow, one of the most prestigious global organizations dedicated to cutting-edge technology. This achievement, announced after a rigorous selection process involving 4,600 applications from 120 countries, reaffirms Celluris’ role as one of the world’s most innovative companies in the field of biotechnology.
What it means to be a Deep Tech Pioneer
The title of Deep Tech Pioneer is awarded by Hello Tomorrow to startups revolutionizing industries through scientific and technological advances. This organization is globally renowned for connecting innovative startups with investors, private companies, and public institutions, creating an ecosystem that accelerates the impact of these technologies.
This achievement places Celluris in a select group of companies transforming the future in areas such as health, energy, and the environment. Moreover, it brings Celluris closer to becoming a finalist in the Global Challenge, an international competition that opens doors to strategic partnerships and global visibility.
Celluris’ journey to recognition
Since its foundation, Celluris has led the development of advanced therapies such as CAR-T immunotherapy, a personalized cancer treatment that uses the patient’s own immune cells to fight the disease.
Headquartered in São Paulo and Switzerland, Celluris combines technological innovation and an ethical approach to make immunotherapy accessible to patients worldwide. This commitment to excellence and accessibility was essential for its selection by Hello Tomorrow.
“Being recognized as a Deep Tech Pioneer validates our work and brings us even closer to our mission of revolutionizing cancer treatment with innovative and accessible solutions,” highlights Patricia Bortman Rozenchan, Celluris’ CEO.
Benefits of recognition by Hello Tomorrow
The achievement of being named a Deep Tech Pioneer is not just a symbolic milestone; it brings a series of practical opportunities for Celluris:
- Connection with investors and strategic partnersHello Tomorrow connects startups to the largest global investor networks and the most innovative organizations in the private and public sectors. For Celluris, this means access to potential partnerships that can accelerate the adoption of CAR-T therapy in international markets.
- International visibilityParticipating in the Global Challenge enhances Celluris’ visibility among industry leaders, researchers, and global investors, strengthening its position as a pioneer in cellular therapies.
- Access to the Global SummitAs part of the program, Celluris will have the opportunity to participate in the Hello Tomorrow Global Summit, one of the most influential events for deep-tech startups. This event serves as a platform to showcase innovations, build networks, and find strategic allies.
- Support in communication and brandingHello Tomorrow offers a communication kit to help startups share this achievement. This is an excellent opportunity to reinforce Celluris’ brand as a disruptive and globally impactful company.
Celluris’ technology and its relevance on the global stage
The CAR-T therapy developed by Celluris stands out for its personalization in cancer treatment, using genetically modified T-cells to efficiently recognize and attack tumors.
Why this matters
According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with millions of new cases diagnosed annually. Therapies like CAR-T offer an innovative approach, especially for patients who do not respond to conventional treatments such as chemotherapy and radiation therapy.
How Celluris plans to maximize this achievement
To fully leverage its recognition as a Deep Tech Pioneer, Celluris is already implementing strategies to strengthen its global presence and expand operations.
- Expanding its collaboration networkThrough Hello Tomorrow, the company seeks to establish partnerships with other startups, pharmaceutical companies, and research institutes.
- Investing in Research and Development (R&D)Celluris will continue to invest in advancing its technologies, ensuring that its treatments align with the highest standards of efficacy and safety.
- Promoting global impactThe company is committed to bringing CAR-T therapy to new markets, impacting patients in regions where access to innovative treatments is still limited.
Hello Tomorrow’s role in building the future
Since its inception, Hello Tomorrow has been a catalyst for innovation, helping startups transform ideas into real solutions. With initiatives such as the Global Challenge and the Global Summit, the organization plays a crucial role in advancing science and technology.
For Celluris, being part of this network is a recognition of its potential for global impact and an opportunity to learn from other pioneering startups.
Recognized work
Being recognized as a Deep Tech Pioneer by Hello Tomorrow is a milestone for Celluris. This recognition validates its innovative work in cellular therapies and opens doors to new collaborations, investments, and global impact.
Celluris is more committed than ever to fulfilling its mission of transforming cancer treatment through CAR-T technology, proving that biotechnology can be a powerful force for saving lives.
To learn more about Celluris’ journey and stay updated on its achievements, visit our blog and follow the latest news in the world of cellular therapies.
